

C2
CW

(i) providing an immunodeficient rodent; and
(ii) introducing tumor cells that induce bone metastasis into the animal by peripheral administration, wherein the metastasis occurs in the animal's own bone.

C3

18. (Amended) The method according to claim 16, wherein the antibody is derived from a mouse.

C4

24. (Twice amended) A method for evaluating efficiencies of treatment against bone metastasis of tumor cells, comprising:

(i) applying a treatment to the rodent bone metastasis model animal according to any one of claims 1 to 5, 7, or 9; and
(ii) comparing the size and/or extent of bone metastasis, and/or symptoms resulting from bone metastasis, with a control animal; thereby evaluating the efficiency of the treatment against bone metastasis of tumor cells.

25. (Twice amended) A method for determining the effect of a test substance on bone metastasis, comprising:

(i) administering the test substance to the rodent bone metastasis model animal according to any of claims 1 to 5, 7, or 9; and
(ii) comparing the size and/or extent of bone metastasis, and/or symptoms resulting from bone metastasis, with a control animal;

thereby determining the effect of the test substance on bone metastasis.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com